CompanySLXN SLXNWNasdaqRamat Gan, L3

Silexion Therapeutics Corp

Silexion Therapeutics develops siRNA therapeutics targeting KRAS-mutant solid tumors.

SEC EDGAR ClinicalTrials.gov

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Silexion doses first patient in Phase 2/3 trial of SIL204 for pancreatic cancer

Sep 30Clinical readoutSilexion Therapeutics Corp

Silexion strikes warrant inducement deal to raise about $0.84 million

Sep 29FinancingSilexion Therapeutics Corp

August 2026

Silexion advances SIL204 into Phase 2/3 trial, reports Q2 2026 results

Aug 14Quarterly updateSilexion Therapeutics Corp

Silexion prices $2.5 million public offering, closes it days later

Aug 13FinancingSilexion Therapeutics Corp

July 2026

Silexion Therapeutics director Amnon Peled resigns from board

Jul 31PeopleSilexion Therapeutics Corp

Silexion activates first site for SIL204 pancreatic cancer trial in Israel

Jul 29Clinical readoutSilexion Therapeutics Corp